Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cytosol

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Cytosol. Displaying page 1 of 1.
    EudraCT Number: 2012-000155-14 Sponsor Protocol Number: V2.0 Start Date*: 2013-12-13
    Sponsor Name:Med. Universität Wien, Universitätsklinik für Innere Medizin II
    Full Title: In vivo assessment of the molecular mechanism of inhaled combination of beclomethasone and formoterol on cell differentiation factors and airway remodelling in COPD
    Medical condition: COPD
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002832-24 Sponsor Protocol Number: CZOL446GDE21 Start Date*: 2005-07-27
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Influence of Zoledronic acid (Zometa®) on bone mineral density and bone ultrasonometry in premenopausal women with hormone receptor positive breast cancer and neoadjuvant or adjuvant chemoendocrine...
    Medical condition: Hormonreceptor positive breast cancer in premenopausal women
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002418-12 Sponsor Protocol Number: CFEM345D2407 Start Date*: 2005-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multicenter safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early brea...
    Medical condition: Bone loss attributed to cessation of ovarian estrogen production is common in postmenopausal women. In postmenopausal women with breast cancer, treatment with an aromatase inhibitor may further red...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-003888-71 Sponsor Protocol Number: CFEM345DDE09 Start Date*: 2005-07-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open phase III trial with Letrozole (Femara®) alone or in combination with Zoledronic acid (Zometa®) as extended adjuvant treatment of postmenopausal patients with primary breast cancer
    Medical condition: prevention of tumortherapy-induced bone loss
    Disease: Version SOC Term Classification Code Term Level
    8.0 10049470 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004018-42 Sponsor Protocol Number: FARM5K3MEE Start Date*: 2006-09-15
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: A phase III study comparing anastrozole, letrozole and exemestane, upfront (for 5 years) or sequentially (for 3 years after 2 years of tamoxifen), as adjuvant treatment of postmenopausal patients ...
    Medical condition: adjuvant hormono-therapy in breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006279 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003889-15 Sponsor Protocol Number: CFEM345DDE10 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open phase III trial with Letrozole (Femara®) as Early Adjuvant treatment of postmenopausal patients with primary breast cancer
    Medical condition: Primary breast cancer in postmenopausal patients
    Disease: Version SOC Term Classification Code Term Level
    8.0 10057654 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001629-23 Sponsor Protocol Number: GIM10-CONSENT Start Date*: 2013-07-19
    Sponsor Name:IRCCS AOU SAN MARTINO- IST
    Full Title: A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatment of post-menopausal patients with endocrine-responsive...
    Medical condition: Breast cancer is the most common form of cancer among women in North America, Europe and Latin America. Beacause nearly 80% of breast cancers are endocrine-responsive tumors, the majority of patien...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002600-33 Sponsor Protocol Number: IBCSG 34-05/ SWOG 0230 Start Date*: 2007-02-16
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: Phase III trial of LHRH analog administration during chemotherapy to reduce ovarian failure following chemotherapy in early stage, hormone-receptor negative breast cancer
    Medical condition: Premenopausal women, Early Stage I, II or IIIA, ER-/ PR- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-019965-27 Sponsor Protocol Number: SAKK21/08 Start Date*: 2011-03-25
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-contr...
    Medical condition: Patient with advanced stage breast cancer (HER2 positive is allowed), i.e. locally advanced or metastatic breast cancer that is not amenable to curative surgery and/or radiation.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002392-27 Sponsor Protocol Number: A5481003 Start Date*: 2009-04-06
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMEN...
    Medical condition: Advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed) HU (Completed) DE (Completed) FR (Completed) IT (Completed) ES (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004263-35 Sponsor Protocol Number: CFEM345D2411 Start Date*: 2006-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomised multi-center Phase IIIb, open label, study of letrozole vs anastrazole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer
    Medical condition: This study will be a head to head comparison of letrozole versus anastrozole in the adjuvant treatment of high risk patients. Post-menopausal patients who recently have undergone their primary surg...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) AT (Completed) DK (Completed) BE (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005573-21 Sponsor Protocol Number: A4021004 Start Date*: 2007-01-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...
    Medical condition: Hormone receptor positive advanced breast cancer in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) NL (Temporarily Halted) GB (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:07:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA